Live Breaking News & Updates on Aprea therapeutics company profile

Stay updated with breaking news from Aprea therapeutics company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FY2028 EPS Estimates for Aprea Therapeutics, Inc. (NASDAQ:APRE) Cut by Analyst

Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) – Analysts at Wedbush reduced their FY2028 earnings per share estimates for Aprea Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $0.77 per share for the year, down from […] ....

Berndr-seizinger , Aprea-therapeutics-company-profile , Aprea-therapeutics-inc , Nasdaq , Aprea-therapeutics , Free-report , Aprea-therapeutic , Get-free-report , Director-bernd , Aprea-therapeutics-daily , Nasdaq-apre

Aprea Therapeutics, Inc. (NASDAQ:APRE) Expected to Post Q1 2025 Earnings of ($1.00) Per Share

Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) – Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Aprea Therapeutics in a research note issued to investors on Tuesday, March 26th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($1.00) per share for the quarter. Wedbush […] ....

Canada , Berndr-seizinger , Geode-capital-management , Nasdaq , Securities-exchange-commission , Royal-bank , Aprea-therapeutics-inc , Millennium-management , Vanguard-group-inc , Aprea-therapeutics-company-profile , Aprea-therapeutics

Aprea Therapeutics (NASDAQ:APRE) Shares Down 4.9%

Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report)’s share price traded down 4.9% on Monday . The company traded as low as $3.61 and last traded at $3.69. 2,872 shares traded hands during trading, a decline of 87% from the average session volume of 22,918 shares. The stock had previously closed at $3.88. Analyst Ratings […] ....

Aprea-therapeutics-inc , Sio-capital-management , Aprea-therapeutics-company-profile , Nasdaq , Renaissance-technologies , Millennium-management , Aprea-therapeutics , Get-free-report , Street-group , Aprea-therapeutics-daily , Nasdaq-apre

Aprea Therapeutics, Inc. to Post Q3 2023 Earnings of ($1.04) Per Share, HC Wainwright Forecasts (NASDAQ:APRE)

Aprea Therapeutics, Inc. to Post Q3 2023 Earnings of ($1.04) Per Share, HC Wainwright Forecasts (NASDAQ:APRE)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Sio-capital-management , Aprea-therapeutics-inc , Nasdaq , Millennium-management , Capital-management , Aprea-therapeutics-company-profile , Aprea-therapeutics , Free-report , Aprea-therapeutic , Therapeutics-trading-down , Get-free-report

Aprea Therapeutics (APRE) to Release Earnings on Monday

Aprea Therapeutics (NASDAQ:APRE – Get Rating) will be releasing its earnings data on Monday, May 15th. Aprea Therapeutics Stock Performance Shares of APRE stock opened at $3.95 on Friday. The company has a market capitalization of $14.74 million, a price-to-earnings ratio of -0.04 and a beta of 0.96. Aprea Therapeutics has a 52 week low […] ....

Aprea-therapeutics-inc , Renaissance-technologies , Aprea-therapeutics-company-profile , Millennium-management , Maxim-group , Aprea-therapeutics , Get-rating , Street-group , Aprea-therapeutics-daily , Nasdaq-apre , Dapre